Innovative and personalized testing for your health

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

An innovative genetic test that helps assess the risk of hereditary diseases even before pregnancy. The study makes it possible to determine whether future parents are carriers of genetic diseases and provides the basis for informed and responsible family planning.

A comprehensive genetic test that identifies the risk of 112 genetic diseases and 254 of their subtypes even before the onset of symptoms. The study allows timely preventive medical actions and provides valuable information for further family planning.

An advanced genetic test that allows to assess the risk of as many as 51 hereditary metabolic diseases in the newborn. The study provides an opportunity to identify possible metabolic disorders at an early stage and to take preventive measures in a timely manner.

A reliable genetic test for pregnant women that allows a safe and early assessment of the risk of chromosomal abnormalities in the fetus. The study is carried out from maternal blood using advanced methods of sequencing and bioinformatics.

An innovative genetic test for the detection of rare, clinically significant monogenic diseases is often overlooked during routine check-ups. The study is carried out from the mother's blood, has high accuracy and is suitable already from the 10th week of pregnancy.

Highly accurate, fast and affordable genetic examination, carried out by the method of digital PCR. From the 12th week of pregnancy, analyzes the extracellular DNA of the fetus and helps to assess the risk of the most common chromosomal abnormalities.

Innovative epigenetic methylation assay for reliable assessment of endometrial cancer risk. The test has an extremely high negative predictive value and helps to avoid invasive diagnostic procedures.

An innovative epigenetic study to help assess the risk of developing cervical cancer. The study is carried out from the same sample as the HPV test and analyzes the methylation changes in the FAM19A4 and miR124-2 genes.

Non-invasive methylation test for early detection of colon cancer or precancerous lesions. Performed at home, evaluates changes in the DNA chain associated with the presence of tumor cells.

An innovative non-invasive test for the early diagnosis of oral squamous cell carcinoma (OSCC) and high-grade dysplasia. The study is based on epigenetic analysis of DNA methylation, carried out from cells of the oral mucosa collected with a special brush - no cuts, no pain, no stress.

An innovative genetic blood test for the early detection of cancer. The study is based on the analysis of genome-wide DNA methylation, which allows to identify cancerous processes and their possible localization even at an early stage. One sample is enough to test for as many as eight types of cancer, from colon to ovarian or prostate cancer.

A comprehensive genetic study that analyzes 90 gene mutations associated with 25 different types of cancer. The study allows you to identify hereditary genetic risks and helps to make informed decisions about cancer prevention, early diagnosis or treatment adjustment.

An innovative genetic test that evaluates the expression of 50 tumor genes and helps assess the risk of breast cancer recurrence in the next 10 years. The study helps to select the most accurate individual treatment plan, combining the effectiveness of treatment with the preservation of the quality of life.

An innovative liquid biopsy test that analyzes tumor DNA circulating in the blood and detects changes in 118 genes important for the selection of a treatment plan and monitoring the course of treatment. The study makes it possible to personalize treatment for patients with solid tumors.

A highly sensitive biopsy study that analyzes 118 cancer-related genes to help select the most accurate treatment strategy for patients with solid tumors.

An innovative whole-exome sequencing assay for detailed tumor genomic profiling. Analyzes thousands of gene mutations to help personalize treatment and create an individualized plan for disease monitoring.

An innovative personalized liquid biopsy study to assess the risk of relapse in patients with stage I-III solid tumors. The study is based on genetic analysis of the tumor and allows extremely early detection of signs of minimal residual disease.

An innovative genetic study covering all coding gene sequences and mitochondrial DNA. Helps to identify the causes of rare hereditary diseases even in the presence of nonspecific symptoms or complex clinical cases.